{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:fda-unapproved-glp1-concerns-record:v1","objectPathId":"fda-unapproved-glp1-concerns-record-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/fda-unapproved-glp1-concerns-record/","json":"https://peptidescanner.com/evidence/v1/objects/fda-unapproved-glp1-concerns-record-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/fda-unapproved-glp1-concerns-record-v1.md"},"story":{"slug":"fda-unapproved-glp1-concerns-record","version":1,"domain":"Safety","dateInSource":"2026-05-31","sourceCheckedAt":"2026-07-29","publishedAt":"2026-07-29","peptideSlugs":["semaglutide","tirzepatide"],"peptides":[{"slug":"semaglutide","url":"https://peptidescanner.com/peptides/semaglutide/"},{"slug":"tirzepatide","url":"https://peptidescanner.com/peptides/tirzepatide/"}]},"claims":[{"id":"headline","text":"FDA details concerns with unapproved GLP-1 products","sourceIds":["fda-unapproved-glp1-concerns-2026"]},{"id":"summary","text":"FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026.","sourceIds":["fda-unapproved-glp1-concerns-2026"]},{"id":"paragraph-1","text":"FDA's page distinguishes FDA-approved products from unapproved versions and compiles agency concerns, enforcement activity, reported quality problems, and adverse-event information dated May 31, 2026.","sourceIds":["fda-unapproved-glp1-concerns-2026"]},{"id":"paragraph-2","text":"This update attributes those statements to FDA and does not evaluate a product, pharmacy, treatment choice, or individual report. It also does not turn FDA's examples into a complete market survey.","sourceIds":["fda-unapproved-glp1-concerns-2026"]}],"sources":[{"id":"fda-unapproved-glp1-concerns-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA concerns with unapproved GLP-1 drugs used for weight loss","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"c92d69fe0165e84f3da26632231b43d4c2b02b820b4fd143e6d867cf495b083b"},"integrity":{"algorithm":"sha256","contentSha256":"0e66f6d40ee2b1e58b41866285e2b35d1c790e32e7639986b9bc98ab1fb34b05"}}